weight regain after stopping glp-1 agonists Two Years GLP-1s, Most Patients Sustain at Least Some Loss Weight loss maintenance after discontinuing
Description
Some meta-analyses show small reductions in body weight (0.5-1 kg) and improvements in fasting glucose, while others show no significant effect

IDF Diabetes Atlas, 2024
The prior authorization process involves your healthcare provider submitting a request to the insurance company, which includes relevant medical information about your condition

Tirzepatide, a dual GIP/GLP-1 receptor agonist (Mounjaro, Zepbound), has demonstrated even greater weight loss in clinical trials

doi: 10.1016/S2213-8587(17)30092-X [DOI] [PubMed] [Google Scholar] 70